PMID- 30504715
OWN - NLM
STAT- MEDLINE
DCOM- 20190911
LR  - 20190911
IS  - 1421-9662 (Electronic)
IS  - 0001-5792 (Linking)
VI  - 141
IP  - 1
DP  - 2019
TI  - Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A 
      Meta-Analysis.
PG  - 32-42
LID - 10.1159/000494487 [doi]
AB  - Deferasirox (DFX) has recently been used to treat thalassemia with iron overload; 
      however, its long-term effectiveness and safety await multi-year studies. In this 
      study, a systematic meta-analysis was performed to assess the effectiveness and 
      safety of DFX in the treatment of thalassemia with iron overload. We performed a 
      systematic electronic literature search for randomized controlled studies of DFX 
      in the Embase, Medline, Cochrane, and Chinese Biomedical Literature (CBM) 
      databases from January 1990 to May 2018. Particular attention was paid to 
      mortality, serum ferritin (SF), liver iron concentration (LIC), myocardial iron 
      concentration, and adverse events (AEs). Six studies comparing DFX with 
      deferoxamine (DFO) and placebo were enrolled. DFX was not better than DFO in 
      lowering SF and LIC, with an exception that high DFX dose (> 30 mg/kg/day) was 
      superior to DFO in LIC. Otherwise, AEs such as gastrointestinal problems appeared 
      to be more common with DFX. DFX does not seem to be superior to DFO at low dose. 
      Similar efficacy seems to be achievable depending on dose. However, the 
      convenient oral administration of DFX has a higher compliance rate.
CI  - (c) 2018 S. Karger AG, Basel.
FAU - Dou, Huihong
AU  - Dou H
AD  - Department of Pediatrics, The First Affiliated Hospital, Guangxi Medical 
      University, Nanning, China.
FAU - Qin, Yuanhan
AU  - Qin Y
AD  - Department of Pediatrics, The First Affiliated Hospital, Guangxi Medical 
      University, Nanning, China, jasminpaper2@163.com.
FAU - Chen, Guoli
AU  - Chen G
AD  - Department of Pediatrics, The First Affiliated Hospital, Guangxi Medical 
      University, Nanning, China.
FAU - Zhao, Yanjun
AU  - Zhao Y
AD  - Department of Pediatrics, The First Affiliated Hospital, Guangxi Medical 
      University, Nanning, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20181130
PL  - Switzerland
TA  - Acta Haematol
JT  - Acta haematologica
JID - 0141053
RN  - 0 (Iron Chelating Agents)
RN  - E1UOL152H7 (Iron)
RN  - J06Y7MXW4D (Deferoxamine)
RN  - V8G4MOF2V9 (Deferasirox)
SB  - IM
CIN - Acta Haematol. 2019;142(3):123-124. PMID: 31189159
MH  - Databases, Factual
MH  - Deferasirox/*therapeutic use
MH  - Deferoxamine/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Iron/analysis
MH  - Iron Chelating Agents/adverse effects/*therapeutic use
MH  - Iron Overload/complications/diagnosis/*drug therapy/mortality
MH  - Myocardium/chemistry
MH  - Odds Ratio
MH  - Thalassemia/complications/*diagnosis
OTO - NOTNLM
OT  - Deferasirox
OT  - Deferoxamine
OT  - Efficacy and safety
OT  - Meta-analysis
OT  - Thalassemia with iron overload
EDAT- 2018/12/07 06:00
MHDA- 2019/09/12 06:00
CRDT- 2018/12/04 06:00
PHST- 2018/02/06 00:00 [received]
PHST- 2018/10/12 00:00 [accepted]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2019/09/12 06:00 [medline]
PHST- 2018/12/04 06:00 [entrez]
AID - 000494487 [pii]
AID - 10.1159/000494487 [doi]
PST - ppublish
SO  - Acta Haematol. 2019;141(1):32-42. doi: 10.1159/000494487. Epub 2018 Nov 30.